Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06589804
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-06
Brief Title:
Testing the Addition of Anti-Cancer Drug Cetuximab to Standard of Care Treatment Pembrolizumab for Returning or Spreading Head and Neck Cancer After Previous Treatment
Sponsor:
None
Organization:
None
Organization Data
Organization:
None
Class:
None
Study ID:
None
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
None
Lead Sponsor Class:
None
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None